DE122010000023I2 - IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung. - Google Patents

IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung.

Info

Publication number
DE122010000023I2
DE122010000023I2 DE201012000023 DE122010000023C DE122010000023I2 DE 122010000023 I2 DE122010000023 I2 DE 122010000023I2 DE 201012000023 DE201012000023 DE 201012000023 DE 122010000023 C DE122010000023 C DE 122010000023C DE 122010000023 I2 DE122010000023 I2 DE 122010000023I2
Authority
DE
Germany
Prior art keywords
antagonist
preparation
fusion proteins
proteins used
receptor fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE201012000023
Other languages
English (en)
Other versions
DE122010000023I1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of DE122010000023I2 publication Critical patent/DE122010000023I2/de
Publication of DE122010000023I1 publication Critical patent/DE122010000023I1/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE201012000023 1998-09-25 2010-04-13 IL-1 Rezeptor Fusionproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Hertstellung. Granted DE122010000023I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using

Publications (2)

Publication Number Publication Date
DE122010000023I2 true DE122010000023I2 (de) 2012-04-26
DE122010000023I1 DE122010000023I1 (de) 2012-04-26

Family

ID=26798712

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69922269T Expired - Lifetime DE69922269T2 (de) 1998-09-25 1999-09-22 IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung
DE69932832T Expired - Lifetime DE69932832T2 (de) 1998-09-25 1999-09-22 Antagonisten auf rezeptorgrundlage und verfahren zu deren herstellung und verwendung
DE201012000023 Granted DE122010000023I1 (de) 1998-09-25 2010-04-13 IL-1 Rezeptor Fusionproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Hertstellung.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69922269T Expired - Lifetime DE69922269T2 (de) 1998-09-25 1999-09-22 IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung
DE69932832T Expired - Lifetime DE69932832T2 (de) 1998-09-25 1999-09-22 Antagonisten auf rezeptorgrundlage und verfahren zu deren herstellung und verwendung

Country Status (19)

Country Link
US (2) US6472179B2 (de)
EP (3) EP1405915A1 (de)
JP (1) JP3902728B2 (de)
CN (1) CN100345970C (de)
AT (2) ATE336583T1 (de)
AU (1) AU758970C (de)
BE (1) BE2010C021I2 (de)
CA (1) CA2345109C (de)
DE (3) DE69922269T2 (de)
DK (1) DK1229047T3 (de)
ES (2) ES2233733T3 (de)
FR (1) FR10C0025I2 (de)
HK (2) HK1035377A1 (de)
IL (2) IL142103A0 (de)
NO (2) NO329976B1 (de)
NZ (1) NZ510720A (de)
PL (1) PL201246B1 (de)
PT (1) PT1229047E (de)
WO (1) WO2000018932A2 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1999037772A1 (en) 1998-01-23 1999-07-29 Immunex Corporation Il-18 receptors
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP2292665B1 (de) 2000-05-26 2015-07-08 Immunex Corporation Verwendung von Interleukin-4 Antikörper und deren Zusammensetzungen
AU2001274234A1 (en) 2000-06-16 2001-12-24 Asterion Limited Binding agents: chimeric ligand/receptor proteins
AU2001290524A1 (en) 2000-08-08 2002-02-18 Zymogenetics Inc. Soluble zcytor 11 cytokine receptors
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
AU2003243189B2 (en) 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
KR101329843B1 (ko) * 2002-11-15 2013-11-14 젠맵 에이/에스 Ｃｄ25에 대한 인간 모노클로날 항체
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
ES2327409T3 (es) 2003-03-26 2009-10-29 Apogenix Gmbh Proteinas de fusion fc mejoradas.
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
EP1664114A1 (de) * 2003-06-11 2006-06-07 Wyeth Verfahren zur herstellung eines polypeptids
SI1648940T1 (sl) * 2003-07-28 2016-08-31 Genentech, Inc. Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A
WO2005024035A1 (en) * 2003-09-05 2005-03-17 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
ATE548388T1 (de) 2003-11-07 2012-03-15 Immunex Corp An den interleukin-4-rezeptor bindende antikörper
ATE395358T1 (de) * 2004-02-27 2008-05-15 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
MXPA06014126A (es) 2004-06-04 2007-07-18 Regeneron Pharma Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
PL1778723T3 (pl) * 2004-08-17 2013-03-29 Regeneron Pharma Preparaty antagonisty IL-1
ES2309427T3 (es) * 2004-08-27 2008-12-16 Conaris Research Institute Ag Secuencias de nucleotidos optimizidas que codifican para sgp130.
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
WO2006031689A2 (en) * 2004-09-13 2006-03-23 Genzyme Corporation Multimeric constructs
RU2007117716A (ru) * 2004-10-12 2008-11-20 Ампротеин Корпорейшн (Us) Химерный белок
EP1812476B1 (de) 2004-10-22 2010-07-21 ZymoGenetics, Inc. Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
EP1848738A1 (de) * 2005-01-25 2007-10-31 Apollo Life Sciences Limited Parameterausgewählte gm-csf, il-3, il-4, il-5 und chimären davon für therapeutische und diagnostische zwecke
EP3195874A1 (de) * 2005-03-25 2017-07-26 Regeneron Pharmaceuticals, Inc. Vegf-antagonistenformulierungen
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
EP1912675B1 (de) 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC B-zell-verringerung mit cd37-spezifischen und cd20-spezifischen bindungsmolekülen
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US7889347B2 (en) 2005-11-21 2011-02-15 Plexera Llc Surface plasmon resonance spectrometer with an actuator driven angle scanning mechanism
EP3811965A1 (de) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonisten zur verwendung in der förderung von knochenwachstum
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
EP2364691B1 (de) 2006-06-16 2013-04-24 Regeneron Pharmaceuticals, Inc. Formulierungen mit VEGF-Antagonisten für eine intravitreale Verabreichung
RS51544B (en) 2006-06-30 2011-06-30 Conaris Research Institute Ag. POBOLJŠANI SGP 130FC DIMERI
US7666423B2 (en) 2006-07-28 2010-02-23 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
RS52538B (en) * 2006-10-20 2013-04-30 Regeneron Pharmaceuticals Inc. USE OF IL-1 ANTAGONISTS FOR THE TREATMENT OF GYTH AND PSEUDOGYCH
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008093756A1 (ja) * 2007-01-30 2008-08-07 Niigata University 生物学的製剤
ES2415666T3 (es) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama
TW202104248A (zh) 2007-02-02 2021-02-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TW201934141A (zh) 2007-02-09 2019-09-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
WO2008113185A1 (en) * 2007-03-19 2008-09-25 National Research Counsil Of Canada Antagonists of ligands and uses thereof
WO2009010539A2 (de) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) form macaca fascicularis
EP2207562B1 (de) 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Activin-actriia antagonisten und verfahren zur verringerung oder inhibierung der fsh-sekretion
WO2009058888A1 (en) * 2007-10-31 2009-05-07 The Scripps Research Institute Combination therapy to treat persistent viral infections
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PL2340031T4 (pl) 2008-08-14 2020-12-28 Acceleron Pharma Inc. Zastosowanie pułapek GDF do leczenia niedokrwistości
EP2326670A4 (de) * 2008-09-17 2014-04-16 Nat Res Council Canada Hetero-multivalente bindemittel für elemente der tgf-beta-superfamilie
AU2009320364B2 (en) 2008-11-26 2013-05-16 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
EP2440577A4 (de) 2009-06-12 2013-01-23 Acceleron Pharma Inc Verkürzte actriib-fc-fusionsproteine
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
AU2012242666A1 (en) 2011-04-15 2013-11-28 Merck Patent Gmbh Anti- IL-1R1 inhibitors for use in cancer
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
SG11201403367YA (en) 2011-12-19 2014-07-30 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
AU2013357427B2 (en) * 2012-12-10 2017-08-31 Universiteit Gent Novel Interleukin-33 inhibitors
EP3985024A1 (de) 2013-02-01 2022-04-20 Atara Biotherapeutics, Inc. Anti-aktivin-a-verbindungen zur behandlung vom ovarialkrebs
LT2956471T (lt) 2013-02-15 2024-06-10 R-Pharm International, Llc Il-1beta inhibitoriaus kompozicija ir jos naudojimas
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
TR201909951T4 (tr) 2014-07-18 2019-07-22 Sanofi Sa Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
EP3226888B1 (de) 2014-12-01 2021-04-21 Ferring B.V. Verabreichung eines selektiven il-6-transsignalisierenden inhibitors
SI3227675T1 (sl) 2014-12-03 2023-07-31 Celgene Corporation Antagonisti aktivin-actrii in uporaba za zdravljenje mielodisplastičnega sindroma
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
JP7240812B2 (ja) * 2015-05-12 2023-03-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多量体タンパク質の純度の決定
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
CN118307682A (zh) 2016-09-27 2024-07-09 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
BR112019021812A2 (pt) 2017-04-21 2020-05-26 Kindred Biosciences, Inc. Molécula receptora de il4/il13 para uso veterinário
CA3077223A1 (en) 2017-09-27 2019-04-04 Epicentrx, Inc. Immunomodulatory fusion proteins
EA202091710A1 (ru) 2018-03-09 2021-02-16 Агенус Инк. Антитела против cd73 и способы их применения
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN110950965B (zh) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 抗人cd123的嵌合抗原受体及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) * 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
DE59109269D1 (de) * 1990-06-28 2005-12-15 Hoechst Ag Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
EP0533006A1 (de) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimäre Interleukin 5-Rezeptor/Immunoglobulin-Polypeptide
US5770401A (en) * 1991-10-15 1998-06-23 Mullarkey; Michael F. Methods and compositions for treating allergic reactions
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU669889B2 (en) * 1992-03-09 1996-06-27 Ludwig Institute For Cancer Research Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
CA2160011A1 (en) * 1993-04-06 1994-10-13 Philip D. Greenberg Chimeric cytokine receptors in lymphocytes
EP0716703A1 (de) * 1993-09-03 1996-06-19 PRENDERGAST, Kenneth, Francis Glycophorin bindende proteine (gbp130) fusionszusammensetzungen
WO1995010611A1 (en) * 1993-10-14 1995-04-20 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
AU3830895A (en) 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU3668897A (en) * 1996-07-17 1998-02-09 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
WO1999037772A1 (en) * 1998-01-23 1999-07-29 Immunex Corporation Il-18 receptors

Also Published As

Publication number Publication date
ES2267300T3 (es) 2007-03-01
IL142103A0 (en) 2002-03-10
US20020164690A1 (en) 2002-11-07
NO2011003I2 (de) 2011-04-11
CA2345109A1 (en) 2000-04-06
DE69922269T2 (de) 2005-12-01
NO2011003I1 (no) 2011-05-02
ATE336583T1 (de) 2006-09-15
JP3902728B2 (ja) 2007-04-11
CA2345109C (en) 2012-12-18
EP1229047A3 (de) 2002-10-02
EP1229047A2 (de) 2002-08-07
ES2233733T3 (es) 2005-06-16
PT1229047E (pt) 2005-03-31
NO20011513L (no) 2001-05-25
NO20011513D0 (no) 2001-03-23
PL348529A1 (en) 2002-06-03
HK1045847B (zh) 2005-03-24
EP1115876A2 (de) 2001-07-18
JP2002525119A (ja) 2002-08-13
DE69932832D1 (de) 2006-09-28
DE69932832T2 (de) 2007-02-08
HK1035377A1 (en) 2001-11-23
FR10C0025I1 (de) 2010-05-21
DE69922269D1 (de) 2004-12-30
IL142103A (en) 2007-07-04
US6472179B2 (en) 2002-10-29
ATE283365T1 (de) 2004-12-15
AU758970B2 (en) 2003-04-03
WO2000018932A3 (en) 2000-11-02
HK1045847A1 (en) 2002-12-13
NZ510720A (en) 2003-11-28
NO329976B1 (no) 2011-01-31
DK1229047T3 (da) 2005-02-21
PL201246B1 (pl) 2009-03-31
WO2000018932A2 (en) 2000-04-06
EP1115876B1 (de) 2006-08-16
AU758970C (en) 2007-05-03
AU6499499A (en) 2000-04-17
WO2000018932A9 (en) 2000-08-31
DE122010000023I1 (de) 2012-04-26
US20020012962A1 (en) 2002-01-31
EP1405915A1 (de) 2004-04-07
CN100345970C (zh) 2007-10-31
EP1229047B1 (de) 2004-11-24
BE2010C021I2 (de) 2018-12-04
CN1357049A (zh) 2002-07-03
FR10C0025I2 (fr) 2011-04-01

Similar Documents

Publication Publication Date Title
DE122010000023I2 (de) IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung.
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO961115L (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE449109T1 (de) Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
CY1112101T1 (el) Νευροτροφικοι παραγοντες
ATE490323T1 (de) Adiponektin-rezeptor und dafür kodierendes gen
CY1114047T1 (el) Νεοι φορεις εκφρασης και χρησεις αυτων
ATE258598T1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
CY1110461T1 (el) Αναλυση της τυποποιησης μονοκλωνικων πρωτεϊνων με τριχοειδη ηλεκτροφορηση και ανοσομετατοπιση
ATE325815T1 (de) Menschliches neurotrimin-homolog
DK1576157T3 (da) Fluorescerende proteiner fra Copepode-arter og fremgangsmåder til anvendelse af samme
DE69534471D1 (de) Peptide, die fähig sind die sh3-domäne des gap-proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
WO1999047558A3 (en) T cell costimulatory proteins, sequences and uses thereof
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
DE69827268D1 (de) Verfahren und zusammensetzungen zur raschen aufreinigung von proteasomen und verfahren zur verwendung entsprechender komponenten
DE69507017D1 (de) Cai-resistenzproteine kodierende dna, und ihre verwendung
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
ATE332974T1 (de) Il-1/tnf-alpha-activated kinase (itak), und verfahren zu ihrer herstellung und verwendung
WO2000006733A3 (en) T cell receptor proteins, nucleic acid molecules, and uses thereof
ATE361367T1 (de) Zusammensetzungen mit fusionsproteinen der kinase wee1, nukleotidsequenzen, expressionsysteme und verfahren zu deren verwendung
ATE439368T1 (de) Schnellreifende fluoreszierende proteine und verfahren zu deren anwendung
DE60308176D1 (de) Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung